New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
10:35 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho said the final CMS pricing for Myriad's BRCA testing represents a cut of about 20%, but that is still less severe than originally outlined. The firm raised its price target on Myriad Genetics to $40 following the ruling, but maintains its Neutral rating on the stock.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MYGN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use